|
|
Article: Biovest International Announces that Revimmune is Profiled in Hopkins Medicine Magazine.(Reprint)
- Article from:
- Business Wire
- Article date:
- January 29, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
TAMPA, Fla. -- Biovest International, Inc. (OTCBB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI), today announced that Hopkins Medicine Magazine has published an article in its Winter 2008 edition profiling Revimmune[TM] for the treatment and prevention of transplant rejection including rejection following a bone marrow transplant. Revimmune is a patent-pending pharmaceutical treatment in late-stage development for the prevention of transplant rejection, with applications to bone marrow transplants for a wide variety of indications including elimination of sickle cell anemia, and other hereditary hemoglobinopathies such as ...
Related newspaper, magazine, and journal articles:
|
|
Article: Biovest International Inc. Review in Progress.
M2 Presswire;
April 17, 2008 ;
700+ words
... ... April 2008-The Maybach Review: Biovest International Inc. Review in Progress(C ... April 17, 2008, we have added Biovest International Inc. (NASDAQ: ABPI) to the ... numerous publicly traded companies Biovest International Inc. started the day up $0 ...
|
|